Metronomic chemotherapy combined with endocrine therapy: are we challenging some dogmas?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Metronomic chemotherapy combined with endocrine therapy: are we challenging some dogmas?

Published:2020-06-30 Issue:7 Volume:20 Page:563-573
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Caparica Rafael¹,De Angelis Claudia¹²,Fêde Ângelo³,Werutsky Gustavo⁴,de Azambuja Evandro¹^ORCID

Affiliation:

1. Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Brussels, Belgium

2. Unit of Medical Oncology 2, Azienda Ospedaliera-Universitaria Pisana, Pisa, Italy

3. Medical Oncology department, AC Camargo Cancer Center, Sao Paulo, Brazil

4. Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil

Funder

no funding

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2020.1782200

Reference74 articles.

1. Breast cancer

2. Endocrine Resistance in Hormone Receptor Positive Breast Cancer–From Mechanism to Therapy

3.

Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?

4. Oral fluoropyrimidine may augment the efficacy of aromatase inhibitor via the down-regulation of estrogen receptor in estrogen-responsive breast cancer xenografts

5. Thymidine phosphorylase is regulated by tamoxifen in T47D breast cancer cell line

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chemotherapy combined with endocrine therapy: Old wine in a new bottle?;Clinical Breast Cancer;2024-08

2. Dose‐dependent bidirectional pharmacological effects of vinorelbine‐based metronomic combination chemotherapy on tumor growth and metastasis and mechanisms in melanoma mouse model;Fundamental & Clinical Pharmacology;2023-07-17

3. Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer;Current Oncology;2023-06-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3